KINETA
Kineta is a biotechnology company engaging in the discovery and development of antiviral therapies and immune-modulating drugs for the treatment of RNA viruses that include hepatitis C, influenza, West Nile virus, and the common cold. Kineta was founded in 2008 and is based in Seattle, Washington.
KINETA
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2008-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.kinetabio.com
Total Employee:
11+
Status:
Active
Contact:
(206)378-0400
Email Addresses:
[email protected]
Total Funding:
81.48 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Domain Not Resolving
Similar Organizations
Spero Therapeutics
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections.
Current Employees Featured
Founder
Investors List
Cheongbo Industrial Co. (CBI)
Cheongbo Industrial Co. (CBI) investment in Corporate Round - Kineta
SCHLAEPFER FAMILY FOUNDATION
SCHLAEPFER FAMILY FOUNDATION investment in Venture Round - Kineta
Wellcome Trust
Wellcome Trust investment in Grant - Kineta
SFC Capital
SFC Capital investment in Venture Round - Kineta
Keiretsu Forum
Keiretsu Forum investment in Venture Round - Kineta
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases investment in Grant - Kineta
Keiretsu Forum Northwest
Keiretsu Forum Northwest investment in Venture Round - Kineta
Keiretsu Capital
Keiretsu Capital investment in Series B - Kineta
AngelMD
AngelMD investment in Funding Round - Kineta
RJ Jones
RJ Jones investment in Venture Round - Kineta
Newest Events participated
Participated in 15th annual Future in Review Conference
on 2017-10-10 as sponsor
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-28 | Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer |
Official Site Inspections
http://www.kinetabio.com Semrush global rank: 5.59 M Semrush visits lastest month: 1.52 K
Unable to get host informations!!!
More informations about "Kineta" on Search Engine
Next-generation immunotherapies for cancer patients …
Kineta fills a void in the biopharmaceutical industry by efficiently advancing first-in-class novel immunotherapies from discovery to proof of concept.See details»
Overview – Kineta Inc.
Mar 12, 2024 Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and …See details»
Kineta - Crunchbase Company Profile & Funding
Organization. Kineta. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Kineta aims at developing edge therapeutics in autoimmune …See details»
Kineta Announces Restructuring and Exploration of Strategic ...
SEATTLE, Feb. 29, 2024 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that …See details»
Kineta Reports Full Year 2023 Financial Results and Provides …
SEATTLE, March 21, 2024 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform …See details»
Pipeline – Kineta Inc.
Kineta’s mission is to develop next-generation immunotherapies that transform patients’ lives. Kineta is focused on developing fully human antibodies that address the …See details»
Kineta Announces Restructuring and Exploration of Strategic …
SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in …See details»
Seattle biotech company Kineta completes merger, …
Dec 19, 2022 Seattle biotech company Kineta completed its merger with Yumanity Therapeutics, a move that makes Kineta a public company. The combined company …See details»
Kineta | LinkedIn
Kineta is a clinical stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Website. http://www.kinetabio.com. Industry....See details»
Kineta, Inc. Announces $3 Million Registered Direct Offering …
SEATTLE, Oct. 04, 2023 — Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel …See details»
Kineta Company Profile - Office Locations, Competitors, Revenue …
Apr 16, 2024 Kineta is a biotechnology company that is engaged in the discovery and development of antiviral therapies and immune-modulating drugs for the treatment of …See details»
Kineta faces shutdown as private placement fails to show up
Feb 29, 2024 Kineta ended the third quarter of 2023 with $7.6 million on hand, compared to $13.1 million at the end of December 2022. The company expected that narrow …See details»
Kineta Inc. | Devex
Kineta® is a nationally-recognized biotechnology company focused on developing leading edge therapeutics in three large high need therapeutic areas: autoimmune disease, viral …See details»
Seattle biotech company Kineta lays off majority of staff
By Taylor Soper on February 29, 2024 at 10:48 am. Kineta announced Thursday that it is laying off 64% of its workforce, or seven employees — including its CEO Shawn …See details»
Kineta to Receive $5 Million Milestone Payment from Merck
SEATTLE, June 29, 2023 — (June 29, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in …See details»
Kineta acquires Kineta (Reverse Merger With Yumanity
Dec 19, 2022 Kineta (Reverse Merger With Yumanity Therapeutics) Yumanity Therapeutics is a biotechnology company that transforms drug discovery for diseases …See details»
Kineta Announces Restructuring and Exploration of Strategic ...
SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in …See details»
Kineta - Contacts, Employees, Board Members, Advisors
Start Your Free Trial. Kineta aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas.See details»
Kineta (Reverse Merger With Yumanity Therapeutics)
Organization. Kineta (Reverse Merger With Yumanity Therapeutics) Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Yumanity …See details»
Kineta Reports Full Year 2023 Financial Results and Provides …
SEATTLE, March 21, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation …See details»